JLE

Hématologie

MENU

Intérêt d’une prophylaxie par lévofloxacine dans le myélome multiple au diagnostic Volume 26, issue 1, Janvier-Février 2020

  • [1] Blimark C., Holmberg E., Mellqvist U.H. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100:107-113.
  • [2] Augustson B.M., Begum G., Dunn J.A. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 – Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23:9219-9226.
  • [3] Drayson M.T., Bowcock S., Planche T. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. The Lancet Oncology. 2019;20:1760-1772.
  • [4] European Centre for Disease Prevention and Control. Data from the ECDC Surveillance Atlas –Antimicrobial resistance. https://ecdc.europa.eu/en/antimicrobial-resistance/surveillance- and-disease-data/data-ecdc (accessed Jan. 21 2019).